Aims To appraise the clinical and genetic evidence that low-density lipoproteins (LDLs)
cause atherosclerotic cardiovascular disease (ASCVD). Methods and results We assessed …

Statins (HMG-CoA reductase inhibitors) are used widely for the treatment of hypercholesterolemia.
They inhibit HMG-CoA reductase competitively, reduce LDL levels more than other …

Background Premature coronary artery disease is a major cause of illness and death in patients
with systemic lupus erythematosus, but little is known about the prevalence, extent, and …

… 18 , Sergio Fazio … Ference BA, Ginsberg HN, Graham I, Ray KK, Packard CJ, Bruckert E,
Hegele RA, Krauss RM, Raal FJ, Schunkert H, Watts GF, Borén J, Fazio S, Horton JD …

Objective The development of these guidelines is mandated by the American Association of
Clinical Endocrinologists (AACE) Board of Directors and American College of …

Adipocyte fatty-acid-binding protein, aP2 (FABP4) is expressed in adipocytes and macrophages,
and integrates inflammatory and metabolic responses. Studies in aP2-deficient mice …

The adipocyte fatty-acid–binding protein, aP2, has an important role in regulating systemic
insulin resistance and lipid metabolism. Here we demonstrate that aP2 is also expressed in …

Background Pharmacologic inhibitors of proprotein convertase subtilisin–kexin type 9 (PCSK9)
are being evaluated in clinical trials for the treatment of cardiovascular disease. The …

Background: Lipoprotein(a) [Lp(a)] may play a causal role in atherosclerosis. PCSK9 (proprotein
convertase subtilisin/kexin 9) inhibitors have been shown to significantly reduce plasma …

Atherosclerosis may be viewed as an inflammatory disease process that includes early
oxidative modification of LDLs, leading to foam cell formation. This “oxidation hypothesis” has …